

JA PCM Private sector: Contribution Briefing & Initial Discussion

8 July – 16:00-17:00

Nancy Frederickx

Els Van Valckenborgh

Marc Van den Bulcke

Scientific & Coordination Manager

Scientific & Lead Coordination Manager

Lead Coordination

Housekeeping rules



1. You are automatically muted – raise your hand if you would like to speak and you will be unmuted



2. You can ask your questions in the chat – the chat will be monitored



3. This webinar is recorded and might be (partially) published on the JA PCM website



4. Please complete the [Expression of Interest Survey](#)

Agenda

- 1 Introduction

- 2 Contribution Opportunities Process

- 3 Private sector perspective: Interactive Exercise

Joint Action (JA): a European instrument

Definition

Joint Actions are co-funded projects under the EU4Health Programme, involving Member States, public-level bodies, and the European Commission to tackle priority health challenges at European level

Aim

Promote cross-border collaboration to share knowledge, tools, and best practices—achieving greater impact than national efforts alone (e.g., policy development, capacity building, and innovation in areas like rare diseases, health equity, and digital health)

Funding

Co-financed by EU grants and national contributions



Read more on

- https://hadea.ec.europa.eu/programmes/eu4health_en
- https://hadea.ec.europa.eu/programmes/eu4health/how-apply_en
- [JA PCM - Public Health - European Commission](#)

JA Personalised Cancer Medicine

Overview

Funding

EU4Health: €±25 million

Total: €31.6 million

Duration

Nov 2025 – Oct 2029

Consortium

151 Partners and 29 countries

- 71 Medical Care Organisation
- 41 Research Organisation
- 32 Public & Governmental Organisation
- 5 Professional Network
- 2 Patient Organisation

Builds on



Project Lead

Sciensano, Belgium



Mission and Vision



Mission

To leverage the potential of PCM within the EU by increasing access to and knowledge of PCM in Europe

Vision

A comprehensive, person-centred approach, addressing multiple perspectives: from the healthy individual, to the cancer patient, to the survivors


Key actions

To create an EU-wide network for cross-border PCM collaboration, and to develop methodologies and tools that can help member states to give access to personalised prevention, diagnosis, treatment and follow-up.

Objectives

- 1 Ensure equitable access to PCM across the cancer pathway
- 2 Share data and best practices (e.g., digital tools, molecular diagnostics, liquid biopsy, molecular tumor board)
- 3 Build knowledge and capacity among healthcare professionals, patients, and the public

Action Plan



The patient journey is addressed through three “arms”, each consisting of two technical work packages (WP) and supported by one or more dedicated pilot applications. In addition, two transversal pilots cover all arms and seven transversal WPs provide overarching support for the technical WPs and pilots.

Seven pilots



Pathway, access, and implementation of **risk-informed cancer prevention** across Europe
Developing and testing care pathways that adapt cancer prevention strategies to individual risk profiles

Implementation readiness for **polygenic risk scores** in screening (breast & prostate cancer)
Exploring how genetic information can help better estimate cancer risk and inform prevention.



Supranational **molecular tumor board** for complex cases/countries without MTB
Strengthening the use of molecular data to support clinical decision-making in multidisciplinary tumour board meetings

Continuous **data collection** via a federated sharing platform

Developing ways to securely collect and analyse real-world cancer data from multiple countries, in order to build larger patient cohorts and generate evidence that can inform decisions on cancer treatments and improve patient outcomes.

- The pilot contains two use cases: 1) Expanding Treatment Space; and 2) Managed Entry Agreements



Digital tools for remote monitoring, needs assessment, self-management, and supportive care
Developing and testing digital tools to support the remote monitoring of patients' health status.



Personalised management of cancer predisposition across the patient journey (CPS Compass)

Integrating information on genetic predisposition into different stages of the patient journey, from screening to follow-up.

LB-ctDNA: Implementation of ctDNA guided decision-making across the patient journey

Assessing the use of blood-based tests to detect, monitor, or follow cancer in a less invasive way.

Pilot Development

Phase 1: Expression of Interest (EOI)

- Consortium members express interest in participating in one or several pilots

Phase 2: Pilot Definition & Planning (in progress)

- Understand participants' expectations and technology readiness (surveys)
- Identify active contributing sites and observer roles

Phase 3: Execution & Implementation

- Expected in early 2027

PILOT
Risk-Informed
Prevention (PARI)

PILOT
Polygenic Risk
Score (PRS)

PILOT/USES CASES
Data Collection & Sharing
and Early Treatment Access

PILOT
Molecular Tumor
Board (MTB)


PILOT
Digital Survivorship
Tool

PILOT
Liquid Biopsy ctDNA

PILOT
Cancer Predisposition CPS
Compass

Webinar 26 May - Summary

- Introduction of the JA PCM project
- Memorandum: Private sector engagement in the JA PCM
- Pilots presentation & value propositions
- Webiste: JA PCM Private Sector Platform



Contribution Opportunities Process

Scope of collaboration:

Two Main Objectives

- 
- 1. Immediate: Collaboration opportunity with JA PCM Pilots through targeted contributions:**
 - Delivered within project timeline and absorption capacity
 - 2. Long-term: Break the silos between public and private PCM stakeholders to**
 - Expand uptake
 - Reduce deployment disparities across the EU
 - Leverage new collaborations

Current Opportunities: Pilots value propositions

- **Medicinal Products & Cancer Treatment**
 - Pilot on Continuous Data Collection in a Federated Data Sharing Platform
- **Next Generation Sequencing: Germline, Liquid Biopsy and Tissue Biopsy Testing**
 - Pilot Implementing ctDNA-guided decision-making across the patient journey
 - Pilot: Polygenic Risk Score Implementation
 - Pilot on personalised management of cancer predisposition across the patient journey
 - Pilot Supranational Molecular Tumour Board
- **Digital Tools & Solutions**
 - Pilot on Digital tools for remote monitoring, needs assessment, self-management and supportive care
- **Consultations: Surveys, workshops**
 - All activities

Contribution Opportunities Process – From Sept 2026

- **Where to find open opportunities**
 - JA PCM Private Sector Platform (*section under construction*)
 - For each Pilot, we will publish opportunity calls for collaboration outlining:
 - Scope of the collaboration; Selection criteria; Timeline; Value proposition; Other relevant information
- **How to apply:**
 - Submit application via a dedicated form on the Platform
 - One application form per opportunity call, multiple calls may be applied to
- **What's next**
 - Selection of several collaborations is possible, will be assessed on a case-by-case basis
 - Shape of the collaboration and contract negotiation will take place directly with the Pilot lead team
 - JA PCM coordination team ensures alignment with the JA PCM Grant Agreement

Contribution Opportunities Process Questions?

japcm.coordination@sciensano.be

Private sector perspective: Interactive Exercise

Scope of collaboration:

Two Main Objectives

1. Immediate: Collaboration opportunity with JA PCM Pilots through targeted contributions:

- Delivered within project timeline and absorption capacity

2. Long-term: Break the silos between public and private PCM stakeholders to

- Expand uptake
- Reduce deployment disparities across the EU
- Leverage new collaborations



Sustainable Framework: From JA PCM to EUnetCCC



- Sustained EU PCM Network
- PCM PPP Framework



- Mission: Establish a unified network integrating cutting-edge cancer research with high-quality clinical care delivery
- <https://eunetccc.eu/>

Stay connected



Japcm.coordination@sciensano.be



www.japcm.eu



www.linkedin.com/company/ja-pcm



www.bsky.app/profile/japcm.bsky.social



www.zenodo.org/communities/japcm/records

Subscribe to our newsletter!
Scan the QR code

